Loading...
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
PURPOSE: Triple-negative breast cancer (TNBC) is related with a poor prognosis as patients do hardly benefit from approved therapies. CD138 (Syndecan-1) is upregulated on human breast cancers. Indatuximab ravtansine (BT062) is an antibody-drug-conjugate that specifically targets CD138-expressing cel...
Na minha lista:
| Udgivet i: | Pharm Res |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer US
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5904230/ https://ncbi.nlm.nih.gov/pubmed/29666962 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11095-018-2400-y |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|